Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale. Read More
Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases.
As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic $813.3 billion, a massive 50% increase over the same period last year. This record-breaking figure
Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead ...
Gilead Foundation today announced a $12 million investment in 33 community‑based organizations across 14 states and the District of Columbia through its Community Health Worker (CHW) Comprehensive HIV Prevention Initiative. This two‑year effort expands CHW‑led prevention models that strengthen knowledge, care navigation, and access to services for communities disproportionately affected by HIV.
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir (DOR/ISL). The data, presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026), confirms that the two-drug combination
